AAA
WINT

Affinity Asset Advisors’s Windtree Therapeutics WINT Stock Holding History

Affinity Asset Advisors’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1
Closed -$105K – 80
2021
Q1 		$105K Buy
+1
New +$216K 0.04% 70

Other funds holding WINT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KC
Kepos Capital New York $73.4M AUM 4.78% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Skandinaviska Enskilda Banken (SEB)
Skandinaviska Enskilda Banken (SEB) Stockholm, Sweden $2.66B AUM 26.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAM
PVG Asset Management Golden, Colorado $173M AUM 64.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

Affinity Asset Advisors's WINT Position: Q2 2021 in Review

Affinity Asset Advisors sold out of Windtree Therapeutics (WINT) in Q2 2021, closing a stake of 1 share — an estimated $105K sold.

Affinity Asset Advisors first reported a position in WINT in Q1 2021 and held it in 1 quarter. The position peaked at $105K in Q1 2021. 14 funds tracked by Wall St. Rank hold WINT as of Q2 2021.

  • Affinity Asset Advisors reported no remaining Windtree Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Affinity Asset Advisors sold 1 Windtree Therapeutics share in Q2 2021, an estimated $105K.
  • Affinity Asset Advisors first reported a position in Windtree Therapeutics in Q1 2021 and held it in 1 quarter.
  • Affinity Asset Advisors's Windtree Therapeutics position peaked at $105K in Q1 2021.
  • 14 funds tracked by Wall St. Rank held Windtree Therapeutics as of Q2 2021.

Based on Affinity Asset Advisors's 13F filing for Q2 2021, filed 13 Aug 2021.